Department of Neonatology, Huangshi Maternity and Child Health Hospital, Huangshi, P.R. China.
Eur Rev Med Pharmacol Sci. 2020 Apr;24(8):4486-4494. doi: 10.26355/eurrev_202004_21031.
To explore the curative effects of vancomycin and cefotaxime combined with gamma globulin respectively in neonatal septicemia and their influences on PCT, CRP, and hs-CRP, so as to provide references for clinical treatment.
181 patients with neonatal septicemia admitted to Huangshi Maternity and Child Health Hospital from April 2012 to August 2014 were selected as the study subjects. Patients treated with vancomycin combined with gamma globulin were selected as group A (96 cases) and those treated with cefotaxime combined with gamma globulin were selected as group B (85 cases). The improvement time of clinical symptoms (milk rejection, nervous system symptoms, body temperature), hospital stays, mortality, medicine curative effects, adverse reactions, complications, and levels of serum CRP, PCT, and hs-CRP of patients before and after treatment were compared between the two groups.
The improvement time of clinical symptoms like body temperature, milk rejection, and neurological symptoms, as well as hospital stays in group A were lower than those in group B (p<0.05); the total effective rate of medicine curative effects in group B was better than that in group A (p<0.05); there was no significant difference in levels of serum CRP, PCT, and hs-CRP between the two groups before treatment (p>0.05); after treatment, levels of serum CRP, PCT, and hs-CRP in both groups decreased significantly, and levels of serum CRP, PCT, and hs-CRP in group B decreased more significantly than those in group A (p<0.05).
Cefotaxime combined with gamma globulin in the treatment of patients with neonatal septicemia has short improvement time in clinical symptoms, high total effective rate of drugs, low mortality, fewer adverse reactions and complications, and can significantly reduce levels of serum CRP, PCT, and hs-CRP, which is worthy of further promotion and application in clinical practice.
分别探讨万古霉素和头孢噻肟联合丙种球蛋白治疗新生儿败血症的疗效及其对 PCT、CRP 和 hs-CRP 的影响，为临床治疗提供参考。
选取 2012 年 4 月至 2014 年 8 月在黄石市妇幼保健院接受治疗的 181 例新生儿败血症患者作为研究对象。将接受万古霉素联合丙种球蛋白治疗的患者设为 A 组（96 例），将接受头孢噻肟联合丙种球蛋白治疗的患者设为 B 组（85 例）。比较两组患者治疗前后临床症状（拒乳、神经系统症状、体温）改善时间、住院时间、死亡率、药物疗效、不良反应、并发症及血清 CRP、PCT、hs-CRP 水平。
A 组体温、拒乳、神经系统症状改善时间及住院时间均低于 B 组（p<0.05）；B 组药物疗效总有效率优于 A 组（p<0.05）；两组治疗前血清 CRP、PCT、hs-CRP 水平比较差异无统计学意义（p>0.05）；治疗后两组血清 CRP、PCT、hs-CRP 水平均明显降低，且 B 组降低幅度明显大于 A 组（p<0.05）。
头孢噻肟联合丙种球蛋白治疗新生儿败血症，可缩短临床症状改善时间，提高药物总有效率，降低死亡率，不良反应及并发症少，能显著降低血清 CRP、PCT、hs-CRP 水平，值得在临床实践中进一步推广应用。
